Opinion Leaders
Medtech is back
-
Marcel Fritsch
Head of Healthcare Funds & Mandates
Bellevue Asset Management AG
After stabilizing in the third quarter, medtech stocks gained significant momentum in the fourth quarter.
Many investors have yet to recognize this positive performance trend. Although the Bellevue Medtech & Services Fund has delivered a positive return of +1.0% year to date, it still lags well behind the global equity market (+17.9%) and the US technology market (+19.5%).
| Total return | Global equities (MXWO net) | Nasdaq-100 (NDX) | Bellevue Medtech & Services | I-EUR |
| Q3 2026 | +2.6% | +1.3% | +2.3% |
| Current Q4 2026 | +2.0% | −4.6% | +16.1% |
| Year-to-date 2026 | +17.9% | +19.5% | +1.0% |
Source: Bloomberg, data as per November 11, 2026 in EUR
AI is no longer a one-way trade
What weighed on the medtech sector’s performance in the first half of the year has now become an important driver of outperformance. Investors increasingly recognize that AI stocks cannot rise indefinitely. Even Goldman Sachs states in a headline: «AI Is No Longer a One-Way Trade.» Capital is seeking quality, growth and valuation discipline, and that is precisely what the medtech sector offers.
Valuations leave considerable room for upside
The fundamental investment drivers have changed little over the years. For the Bellevue Medtech & Services Fund, we continue to expect average annual revenue growth of around 8% and earnings growth of 13% through 2029. Even after the recent market recovery, the medtech sector remains attractively valued. Trading at a price-to-earnings ratio of 19.6x based on expected earnings over the next 12 months, it stands around 18% below its average since 2022 (23.9x) and around 27% below its pre-Covid-19 level (27.0x).

All data in USD, analysis period March 7, 2022 to September 30, 2026; MSCI Healthcare Equipment & Supplies (Medtech): MXWO0HE Index; Source: Bellevue Asset Management, Bloomberg (data)
US elections provide a tailwind
Following the Democrats’ victory in the midterm elections, investors see hospitals (as customers of medtech companies), and consequently the medtech sector, as beneficiaries, for example through improved funding for Medicaid and the Affordable Care Act (ACA). At the same time, sweeping policy changes are unlikely to pass with a Republican US president in the White House holding veto power. We therefore consider the risk of regulatory intervention in the healthcare sector to be limited. By contrast, market participants see rising regulatory risks in the technology sector. The chart below shows a strong negative correlation between the medtech and semiconductor sectors.

Source: Bloomberg, data as of 11 November 2026 in EUR
Our conclusion
The rotation has only just begun: The performance gap relative to the global equity market and the technology sector points to substantial remaining catch-up potential. For investors reviewing their equity allocation, medtech offers an attractive combination of defensive growth, strong resilience, attractive valuations and low correlation with the technology sector. In our view, investors seeking to reduce their equity exposure should do so primarily outside the medtech sector.

Source: Bellevue Asset Management AG, Bloomberg. Data as of 11 November 2026 in EUR. Past performance is not a reliable indicator of future results.
__
Disclaimer
This press release is issued by Bellevue Asset Management AG, which is an authorized asset manager subject to the supervision of the Swiss Financial Market Supervisory Authority (“FINMA”) and acts as an Investment Manager of the Bellevue Funds (Lux) SICAV. Bellevue Medtech & Services Fund is a subfund of Bellevue Funds (Lux). The information and data presented in this press release are not to be considered as an offer to buy or sell or an invitation to subscribe any securities or financial instruments. For potential investors in Singapore Investment returns may increase or decrease due to exchange rate fluctuations. The fund(s) is not authorized or recognized by the Monetary Authority of Singapore (the “MAS”) and its shares are not allowed to be offered to the retail public. The Sub-Fund is a restricted scheme under the Sixth Schedule to the Securities and Futures (Offers of Investments) (Collective Investment Schemes) Regulations of Singapore. This press release is not a prospectus as defined in the SFA and accordingly, statutory liability under the SFA in relation to the content of prospectuses does not apply. The MAS assumes no responsibility for the contents of this Information Memorandum. You should consider carefully whether the investment is suitable for you and whether you are permitted (under the SFA, and any laws or regulations that are applicable to you) to make an investment in the Shares. If in doubt, you should consult your legal or professional advisor. This Information Memorandum has not been registered as a prospectus with the MAS. Accordingly, this Information Memorandum, the Prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of Shares may not be circulated or distributed, nor may Shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to any persons in Singapore except in accordance with the restrictions and conditions under the SFA. By subscribing for Shares pursuant to the exempt offer under this Information Memorandum, you are required to comply with restrictions and conditions under the SFA in relation to your offer, holding and subsequent transfer of Shares.
Hong Kong: This section has been prepared solely for Hong Kong investors who invest or propose to invest in Shares of Bellevue Funds (Lux) (the “Company”) in Hong Kong. Investors in Hong Kong should read this supplement in conjunction with the Prospectus for the Company (the “Prospectus”). References to the Prospectus are to be taken as references to that document as supplemented hereby. In addition, words and expressions defined in the Prospectus, unless otherwise defined below, shall bear the same meaning when used herein.
Prospectus, Key Information Document (“PRIIP-KID”), the articles of association as well as the annual and semi-annual reports of the Bellevue Funds under Luxembourg law are available free of charge from Bellevue Asset Management AG, Theaterstrasse 12, CH-8001 Zürich.